P16 deletion in sarcomatoid tumors of the lung and pleura

Archives of Pathology and Laboratory Medicine

Volumn 137, Issue 5, 2013, Pages 632-636

  Tochigi, Naobumi ^a   Attanoos, Richard ^b   Chirieac, Lucian R ^c   Allen, Timothy Craig ^d   Cagle, Philip T ^e   Dacic, Sanja ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b LLANDOUGH HOSPITAL   (United Kingdom)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF TEXAS AT TYLER   (United States)

^e HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

P16 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

ADULT; ARTICLE; GENE DELETION; GENETICS; HUMAN; LUNG TUMOR; MESOTHELIOMA; PATHOLOGY; PLEURA TUMOR; PROGNOSIS; SARCOMA;

ADULT; GENE DELETION; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; NEOPLASM PROTEINS; PLEURAL NEOPLASMS; PROGNOSIS; SARCOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 84877969898     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2012-0108-OA     Document Type: Article

References (35)

1. Cury PM, Butcher DN, Fisher C, Corrin B, Nicholson AG. Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura. Mod Pathol. 2000;13(2):107-112. (Pubitemid 30109095)
2. Lucas DR, Pass HI, Madan SK, et al. Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study. Histopathology. 2003;42(3):270-279. (Pubitemid 36356860)
3. Kushitani K, Takeshima Y, Amatya VJ, Furonaka O, Sakatani A, Inai K. Differential diagnosis of sarcomatoid mesothelioma from true sarcoma and sarcomatoid carcinoma using immunohistochemistry. Pathol Int. 2008;58(2):75-83.
4. Pelosi G, Sonzogni A, De Pas T, et al. Review article: pulmonary sarcomatoid carcinomas: a practical overview. Int J Surg Pathol. 2010;18(2): 103-120.
5. Attanoos RL, Dojcinov SD,Webb R, Gibbs AR. Anti-mesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms. Histopathology. 2000;37(3):224-231.
6. Weinbreck N, Vignaud JM, Begueret H, et al. SYT-SSX fusion is absent in sarcomatoid mesothelioma allowing its distinction from synovial sarcoma of the pleura. Mod Pathol. 2007;20(6):617-621. (Pubitemid 46788868)
7. Musti M, Kettunen E, Dragonieri S, et al. Cytogenetic and molecular genetic changes in malignant mesothelioma. Cancer Genet Cytogenet. 2006; 170(1):9-15. (Pubitemid 44349011)
8. Illei PB, Rusch VW, Zakowski MF, Ladanyi M. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res. 2003;9(6):2108-2113. (Pubitemid 36687632)
9. Singhal S, Wiewrodt R, Malden LD, et al. Gene expression profiling of malignant mesothelioma. Clin Cancer Res. 2003;9(8):3080-3097. (Pubitemid 36993271)
10. Lopez-Rios F, Chuai S, Flores R, et al. Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res. 2006;66(6):2970-2979.
11. Monaco SE, Shuai Y, Bansal M, Krasinskas AM, Dacic S. The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations. Am J Clin Pathol. 2011;135(4):619-627.
12. Illei PB, Ladanyi M, Rusch VW, Zakowski MF. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions. Cancer. 2003;99(1):51-56. (Pubitemid 36267967)
13. Chiosea S, Krasinskas A, Cagle PT, Mitchell KA, Zander DS, Dacic S. Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. Mod Pathol. 2008;21(6):742-747. (Pubitemid 351744840)
14. Xio S, Li D, Vijg J, Sugarbaker DJ, Corson JM, Fletcher JA. Codeletion of p15 and p16 in primary malignant mesothelioma. Oncogene. 1995;11(3):511-515.
15. Prins JB, Williamson KA, Kamp MM, et al. The gene for the cyclindependent-kinase-4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma. Int J Cancer. 1998;75(4):649-653. (Pubitemid 28094115)
16. Cheng JQ, Jhanwar SC, Klein WM, et al. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res. 1994;54(21): 5547-5551.
17. Hirao T, Bueno R, Chen CJ, Gordon GJ, Heilig E, Kelsey KT. Alterations of the p16(INK4) locus in human malignant mesothelial tumors. Carcinogenesis. 2002;23(7):1127-1130. (Pubitemid 34814769)
18. Shapiro GI, Park JE, Edwards CD, et al. Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines. Cancer Res. 1995;55(24): 6200-6209.
19. Belinsky SA, Nikula KJ, Palmisano WA, et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A. 1998;95(20):11891-11896.
20. Borczuk AC, Taub RN, Hesdorffer M, et al. P16 loss and mitotic activity predict poor survival in patients with peritoneal malignant mesothelioma. Clin Cancer Res. 2005;11(9):3303-3308. (Pubitemid 40627879)
21. Jarmalaite S, Kannio A, Anttila S, Lazutka JR, Husgafvel-Pursiainen K. Aberrant p16 promoter methylation in smokers and former smokers with nonsmall cell lung cancer. Int J Cancer. 2003;106(6):913-918. (Pubitemid 37071670)
22. Kim DH, Nelson HH, Wiencke JK, et al. p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res. 2001;61(8):3419-3424. (Pubitemid 32695035)
23. Gazzeri S, Della Valle V, Chaussade L, Brambilla C, Larsen CJ, Brambilla E. The human p19ARF protein encoded by the beta transcript of the p16INK4a gene is frequently lost in small cell lung cancer. Cancer Res. 1998;58(17):3926-3931. (Pubitemid 28405650)
24. Yanagawa N, Tamura G, Oizumi H, Takahashi N, Shimazaki Y, Motoyama T. Frequent epigenetic silencing of the p16 gene in non-small cell lung cancers of tobacco smokers. Jpn J Cancer Res. 2002;93(10):1107-1113. (Pubitemid 35314955)
25. Iwakawa R, Kohno T, Anami Y, et al. Association of p16 homozygous deletions with clinicopathologic characteristics and EGFR/KRAS/p53 mutations in lung adenocarcinoma. Clin Cancer Res. 2008;14(12):3746-3753.
26. Kraunz KS, Nelson HH, Lemos M, Godleski JJ, Wiencke JK, Kelsey KT. Homozygous deletion of p16INK4a and tobacco carcinogen exposure in nonsmall cell lung cancer. Int J Cancer. 2006;118(6):1364-1369.
27. Andujar P, Wang J, Descatha A, et al. p16INK4A inactivation mechanisms in non-small-cell lung cancer patients occupationally exposed to asbestos. Lung Cancer. 2010;67(1):23-30.
28. Orlow I, Drobnjak M, Zhang ZF, et al. Alterations of INK4A and INK4B genes in adult soft tissue sarcomas: effect on survival. J Natl Cancer Inst. 1999; 91(1):73-79. (Pubitemid 29042446)
29. Subramaniam MM, Noguera R, Piqueras M, Navarro S, Lopez-Guerrero JA, Llombart-Bosch A. p16INK4A (CDKN2A) gene deletion is a frequent genetic event in synovial sarcomas. Am J Clin Pathol. 2006;126(6):866-874. (Pubitemid 44901838)
30. Vallat-Decouvelaere AV, Dry SM, Fletcher CD. Atypical and malignant solitary fibrous tumors in extrathoracic locations: evidence of their comparability to intra-thoracic tumors. Am J Surg Pathol. 1998;22(12):1501-1511. (Pubitemid 28550645)
31. Gold JS, Antonescu CR, Hajdu C, et al. Clinicopathologic correlates of solitary fibrous tumors. Cancer. 2002;94(4):1057-1068. (Pubitemid 34150861)
32. Havlik DM, Farnath DA, Bocklage T. Solitary fibrous tumor of the orbit with a t(9;22)(q31;p13). Arch Pathol Lab Med. 2000;124(5):756-758. (Pubitemid 30321884)
33. Cerda-Nicolas M, Lopez-Gines C, Gil-Benso R, et al. Solitary fibrous tumor of the orbit: morphological, cytogenetic and molecular features. Neuropathology. 2006;26(6):557-563. (Pubitemid 44800293)
34. Liu CC, Wang HW, Li FY, et al. Solitary fibrous tumors of the pleura: clinicopathological characteristics, immunohistochemical profiles, and surgical outcomes with long-term follow-up. Thorac Cardiovasc Surg. 2008;56(5):291-297.
35. Mosquera JM, Fletcher CD. Expanding the spectrum of malignant progression in solitary fibrous tumors: a study of 8 cases with a discrete anaplastic component-is this dedifferentiated SFT? Am J Surg Pathol. 2009;33(9): 1314-1321.